Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis

(2012) Swarnali Acharyya et al.   CELL

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

(2012) Alicia S Chung et al.   JOURNAL OF PATHOLOGY

Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography

(2011) Xiao-Dong Zhu et al.   BMC CANCER

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy

(2011) R. G. Bagley et al.   CLINICAL CANCER RESEARCH

The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

(2011) Thomas Powles et al.   EUROPEAN UROLOGY

Zoledronic acid: multiplicity of use across the cancer continuum

(2011) Allan Lipton   Expert Review of Anticancer Therapy

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Antiangiogenic therapy, hypoxia and metastasis: risky liaisons, or not?

(2011) Katrien De Bock et al.   Nature Reviews Clinical Oncology

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma

(2010) J D Veltman et al.   BRITISH JOURNAL OF CANCER

Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects

(2010) W. Zhang et al.   CLINICAL CANCER RESEARCH

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling

(2010) R. S. Bhatt et al.   MOLECULAR CANCER THERAPEUTICS

Peering into the aftermath: The inhospitable host?

(2010) Robert S Kerbel et al.   NATURE MEDICINE

Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

(2009) Sonja Loges et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

(2009) Joshua Ö. Haznedar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Human Hepatocellular Carcinoma Tumor-derived Endothelial Cells Manifest Increased Angiogenesis Capability and Drug Resistance Compared with Normal Endothelial Cells

(2009) Y.-Q. Xiong et al.   CLINICAL CANCER RESEARCH

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2009) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

(2009) Emer O. Hanrahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009

(2009) Donald Poon et al.   LANCET ONCOLOGY

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery

(2008) W. Cacheux et al.   ANNALS OF ONCOLOGY

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

TSU68 Prevents Liver Metastasis of Colon Cancer Xenografts by Modulating the Premetastatic Niche

(2008) M. Yamamoto et al.   CANCER RESEARCH

Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice

(2008) Bi-Wei Yang et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE